X

Articles

04Jan

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

0 Comments | | Return |

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 convalescent plasma.  The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment.  Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.

We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines. 

 

 

 

Related

CTS Charlotte Implements New Laboratory Information System

On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...

Read More >

Notification of Form Revisions to Implement on September 2, 2019

The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...

Read More >

Preparing for Hurricane Florence

As the US coast prepares for Hurricane Florence to make landfall, we have received importan...

Read More >

Reminder-Check flights and cargo hours for the Labor Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

New Online Learning Center with New Content

The new online Learning Center with new content can still be found under the “Training” folder on ...

Read More >

Reminder- Health and Human Services (HHS) email notifications for WNV reactives

Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...

Read More >

Subscribe here to receive CTS updates!

Name